Related Experiment Video

Updated: Jun 12, 2026

Molecular and Immunologic Techniques in a Genetically Engineered Mouse Model of Gastrointestinal Stromal Tumor
07:21

Molecular and Immunologic Techniques in a Genetically Engineered Mouse Model of Gastrointestinal Stromal Tumor

Published on: May 2, 2022

Molecular basis and management of gastrointestinal stromal tumors

Ulas D Bayraktar1, Soley Bayraktar, Caio M Rocha-Lima

  • 1Division of Hematology and Oncology, Sylvester Comprehensive Cancer Center, University of Miami, 1475 NW 12th Ave, St 3300, Miami, FL 33136, USA. ubayraktar@med.miami.edu

World Journal of Gastroenterology
|June 10, 2010
PubMed

Insights

Targeting KIT, a receptor tyrosine kinase, has transformed gastrointestinal stromal tumor (GIST) treatment. This review covers KIT-targeted therapies like imatinib and sunitinib, and new options for resistant GISTs.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Molecularly targeted agents have revolutionized cancer management.
  • KIT receptor tyrosine kinase plays a crucial role in gastrointestinal stromal tumors (GISTs).
  • Imatinib and sunitinib are approved KIT-targeted tyrosine kinase inhibitors for GIST treatment.

Purpose of the Study:

  • To review the molecular pathogenesis of GISTs.
  • To discuss the role of imatinib and sunitinib in GIST treatment.
  • To introduce novel therapeutic strategies for resistant GISTs.

Main Methods:

  • Literature review of molecular pathogenesis.
  • Analysis of clinical data for imatinib and sunitinib efficacy.
  • Exploration of emerging therapeutic targets and agents.

Main Results:

  • KIT signaling pathways are central to GIST development.
  • Imatinib and sunitinib are effective first- and second-line treatments for GISTs.
  • Drug resistance necessitates the development of novel therapeutic options.

Conclusions:

  • Targeting KIT has established a new treatment paradigm for GISTs.
  • Understanding GIST molecular pathogenesis is key to effective therapy.
  • Novel agents are crucial for overcoming resistance to current KIT-targeted therapies.

More Related Videos

Robotic Duodenal Sleeve Resection for Gastrointestinal Stromal Tumor with Rare Exon 8 KIT Mutation Following Neoadjuvant Imatinib06:43

Robotic Duodenal Sleeve Resection for Gastrointestinal Stromal Tumor with Rare Exon 8 KIT Mutation Following Neoadjuvant Imatinib

Published on: April 3, 2026

Related Concept Videos

Inflammatory Bowel Disease V: Surgical Management01:21

Inflammatory Bowel Disease V: Surgical Management

Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...